Novo Nordisk agreed to acquire global rights to zaltenibart, an Omeros antibody that inhibits MASP‑3, in a deal worth up to $2.1 billion including milestones. Novo will fund pivotal testing in paroxysmal nocturnal hemoglobinuria (PNH) and explore additional blood and kidney disorder indications. Omeros receives $340 million up front and near‑term milestones, plus royalties. The transaction transfers a mid‑stage complement‑system asset with positive Phase II signals for both intravascular and extravascular hemolysis to a company with large rare‑disease commercial scale and development capacity. Novo frames the program as potentially differentiated from C5 inhibitors on the market by targeting MASP‑3, which may affect both intravascular and extravascular hemolysis. Analysts noted a sharp market reaction to the deal and repositioning of Omeros stock.